Cover Image
Market Research Report
Product code 

Microneedle Drug Delivery Systems Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)

Published: | Mordor Intelligence Pvt Ltd | 120 Pages | Delivery time: 2-3 business days


Back to Top
Microneedle Drug Delivery Systems Market - Growth, Trends, Covid-19 Impact, and Forecasts (2022 - 2027)
Published: April 28, 2022
Mordor Intelligence Pvt Ltd
Content info: 120 Pages
Delivery time: 2-3 business days
  • Description
  • Table of Contents

The Microneedle drug delivery systems market is projected to register a CAGR of 7.8% during the forecast period of 2022-2027.

The healthcare system has witnessed enormous challenges as a result of the COVID-19 pandemic. All outpatient treatments were postponed or restricted during the COVID-19 pandemic to ​reduce the risk of viral transmission as most chronic pain therapies were regarded as non-urgent. On the other hand, COVID-19 provides ample growth opportunities to the studied market that is likely to dramatically increase patient footfall post-pandemic. Since then, demand for COVID-19 vaccines is anticipated to increase, and the market for microneedle drug delivery systems is estimated to expand more quickly as these systems are non-invasive and painless.

Microneedle patch immunization has been extensively studied for its non-invasive technique. The vaccine hesitancy has been listed as one of the top ten threats to global health by the World Health Organization. A survey by Lazarus JV et al., in October 2020 showed that around 53.1% of the studied people opted not to be vaccinated or were not sure whether they should be vaccinated. The vaccine hesitancy is usually a result of needle phobia and fear of pain and complications. The growing demand for the needle less, pain less microneedle patches is expected to propel the growth of the market.

The injectables have been a concern because of its invasive nature, thermo-stability issues and necessity for highly skilled practitioners. Needlestick injuries (NSIs) are a serious concern to healthcare professionals. According to the World Health Organization, health care workers encounter more than two million NSIs annually. The complications associated with the injectables paved way for the expansion of the microneedle or the microarray drug delivery systems market.

There has been a rise in the prevalence of chronic diseases such as diabetes, cancer, heart disease and stroke. Other lifestyle diseases such as chronic lung disease, chronic kidney disease, Alzheimer's disease have also been on the rise over the past decade. In 2021, the Center for Disease Control and Prevention has listed that in the United States, six in ten adults have at least one chronic disease and four in ten adults have two or more. The increasing prevalence of such chronic diseases has also augmented the innovations in the microneedle drug delivery system. Thus, the microneedle drug delivery systems market is predicted to expand in the forecast period.

Key Market Trends

The Dissolvable Microneedle Drug Delivery System Segment is Expected to Hold a Major Market Share in the Microneedle Drug Delivery Systems Market

The dissolvable microneedle drug delivery systems are made mainly from dissolvable or biodegradable polymers. The dissolvable microneedles are a great option for the delivery of low molecular weight peptides, enzymes, drugs, vaccines and biotherapeutics. The increased interest in the research of the dissolvable microneedles is expected to boost the growth of the market.

For instance, in May 2021, HTL Biotechnology and Terasaki Institute of Biomedical Innovation announced a MOU that would help research in the microneedle and bioprinting technoloiges for application in dermatology and drug delivery. A team from from Terasaki Institute of Biomedical Innovation, in October 2020, has developed a novel biodegradable microneedle patch for gene therapy applications. The rise in the recognition of the dissolvable microneedle drug delivery systems by the government and healthcare research organizations is predicted to help the development of the segment in the market.

Researchers form the National Science Foundation of China and Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences, in September 2021, have fabricated a biodegradable microneedle patch for delivering DNA based SARS-CoV-2 vaccine nanoparticles.The microneedle patches have a significant advantage over conventional vaccines in that they could be stored at room temperature for at least 30 days. This could improve the global accessibility for the COVID-19 vaccine.

The resilient, non invasive, efficient nature of the dissolvable microneedle drug delivery system is anticipated to aid in the advancement of the market in the forecast period.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period.

The rise in the adoption of highly advanced techniques and systems in fabrication of microneedles and the technological advancements made in microneedle drug delivery is expected to boost the growth of the market in the North American region. The high awareness among the population on the availability of novel microneedle drug delivery system products in the market contributes to the high market growth in the region.

Also, the increasing prevalence of chronic diseases among people in the United States is expected to drive the demand for the Microneedle drug delivery systems market in this region. According to the National Diabetes Statistics Report, in 2020, around 37.3 million people in the United States were found to have diabetes; around 96 million adults were found to have pre diabetes. The National Kidney Foundation in 2020 has estimated that about 36 million adults in the US have chronic kidney diseases. A report by the Center for Disease prevention and Control in 2020 showed that around 15.7 million Americans are affected by Chronic lower respiratory Disease. The massive incidence of the chronic diseases among the population in the United States is expected to advance the expansion of the microneedle drug delivery system market in the North American region.

Thus the increasing awareness about the importance of Microneedle drug delivery systems coupled with increasing investment in the health care department is known to propel the growth of the market in this region.

Competitive Landscape

The Microneedle drug delivery systems market is fragmented competitive and consists of several major players. In terms of market share, a few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are 3M Company, Becton, Dickinson and Company, Raphas Co. Ltd., Nanopass Technologies, Corium Inc., Nitto Denko Corporation, Zealand Pharma A/S, nanoBioSciences, LLC, Micropoint Technologies, LTS Lohmann Therapie-Systeme AG and others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support
Product Code: 72572



  • 1.1 Study Assumptions and market definition
  • 1.2 Scope of the Study




  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Prevalence of Chronic Diseases and Lifestyle Disorders
    • 4.2.2 Increasing Research on Painless Drug Delivery and Technological Advancement
    • 4.2.3 Increasing Demand for a Safer Substitute to Conventional Hypodermic Injections
  • 4.3 Market Restraints
    • 4.3.1 Limited Number of Approved Products and Complications / Risks Associated with Microneedles
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry


  • 5.1 By Product Type
    • 5.1.1 Solid
    • 5.1.2 Hollow
    • 5.1.3 Coated
    • 5.1.4 Dissolvable
  • 5.2 By Application
    • 5.2.1 Drug Delivery
    • 5.2.2 Vaccine Delivery
    • 5.2.3 Dermatology
    • 5.2.4 Others
  • 5.3 Geography
    • 5.3.1 North America
      • United States
      • Canada
      • Mexico
    • 5.3.2 Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Rest of Europe
    • 5.3.3 Asia-Pacific
      • China
      • Japan
      • India
      • Australia
      • South Korea
      • Rest of Asia-Pacific
    • 5.3.4 Middle-East and Africa
      • GCC
      • South Africa
      • Rest of Middle-East and Africa
    • 5.3.5 South America
      • Brazil
      • Argentina
      • Rest of South America


  • 6.1 Company Profiles
    • 6.1.1 3M Company
    • 6.1.2 Becton, Dickinson and Company
    • 6.1.3 Raphas Co. Ltd.
    • 6.1.4 Nanopass Technologies
    • 6.1.5 Corium Inc.
    • 6.1.6 Nitto Denko Corporation
    • 6.1.7 Zealand Pharma A/S
    • 6.1.8 nanoBioSciences, LLC
    • 6.1.9 Micropoint Technologies
    • 6.1.10 LTS Lohmann Therapie-Systeme AG